Back to search results

The DC Cohort Longitudinal HIV Status Neutral Study

This study, called the DC Cohort, is observing people living with HIV (Human Immunodeficiency Virus) or those at higher risk of getting HIV in Washington, D.C. The goal is to understand how HIV affects people over time and to improve the care they receive. Researchers will collect information from your medical records, including your health status, treatments, and lab results. The study aims to see how many people with HIV achieve viral suppression (when the amount of HIV in the blood is very low) and to track health outcomes for those at higher risk of getting HIV. You can join if you are receiving HIV care at one of the participating clinics in D.C. and are 18 or older, or a minor with parent/guardian consent. This is an ongoing study, and researchers are still gathering information.

Study design
This is an observational study, meaning researchers will collect information from existing medical records. It plans to include up to 19,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants with HIV will be followed for an average of 10 years, and those at higher risk for acquiring HIV will be followed for an average of 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01206920

The DC Cohort Longitudinal HIV Status Neutral Study

Recruiting
Not specifiedAll AgesObservational
George Washington University
~19,000 participants
Updated 2026-02-02 on ClinicalTrials.gov

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
viral suppression among persons with HIV
Measured over through study completion, an average of 10 years from enrollment to the end of study follow up
+1 more outcome measured

Conditions

HIV
AIDS

Explore related trials

Acquired Immunodeficiency SyndromeHepatitis B InfectionHIV InfectionHIV Infection

Where it's being run

14 sites across 1 states
District of Columbia14

Study leadership

  • Amanda D Castel, MD, MPH · PRINCIPAL_INVESTIGATOR · George Washington University

Who to contact

Amanda D Castel, MD, MPH
[email protected]
202-994-8325
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.
Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.
Patient is a minor who is consented by a parent or legal guardian.
PrEP (e.g., TDF/FTC, Descovy, Apretude)
Combination ART indicative of nPEP in an HIV-uninfected person
Persons receiving an antiretroviral prescription indicative of DoxyPEP Doxycycline 200mg PO taken within 72 hrs of unprotected sexual encounter (or variations thereof where clearly not prescribed as a treatment course)
Test positive for ≥1 bacterial STI (positive gonorrhea (GC/NG) or chlamydia (CT) test or positive syphilis test requiring treatment within one year)
2 bacterial STI (GC, chlamydia, syphilis) tests at 2 or more different encounters
2 HIV tests at 2 or more different encounters
Patient requesting PrEP at their clinical visit
Patient requesting nPEP at their clinical visit
People who identify as injecting drugs

Exclusion

Patient is unable or refuses to provide informed consent.
Minor children ages 12 through 17 who are unaware of their HIV status

What this trial measures

  • viral suppression among persons with HIVthrough study completion, an average of 10 years from enrollment to the end of study follow up

    The study will assess rates of viral suppression (defined as an HIV RNA test less than 200 copies/ml) from enrollment to 10 years post enrollment.

  • clinical outcomes persons at higher risk for acquiring HIVthrough study completion, an average of 5 years from enrollment to the end of study follow up period

    Persons who are receiving HIV preventive services will be followed longitudinally to assess time to HIV positivity from baseline to 5 years post enrollment